Allarity Therapeutics Faces Class Action Lawsuit Over Alleged Misleading Statements and SEC Investigation

### Allarity Therapeutics Faces Class Action Lawsuit Over Alleged Misleading Statements

Allarity Therapeutics, Inc. (NASDAQ: ALLR) is currently embroiled in a major legal challenge as multiple law firms announce opportunities for investors to participate in a securities fraud class action lawsuit. The class period for the lawsuit spans from May 17, 2022, to July 19, 2024, and aims to address allegations that the company and its former officers made materially false and misleading statements regarding the regulatory status of its drug candidate, Dovitinib. The lawsuit claims that Allarity overstated the prospects of the New Drug Application (NDA) for Dovitinib and failed to disclose significant risks associated with its approval process, leading to heightened regulatory scrutiny and potential enforcement actions.

The lawsuit comes on the heels of critical disclosures that have negatively impacted Allarity's reputation and stock price. On February 6, 2023, the company announced an ongoing investigation by the SEC regarding its communications related to the Dovitinib NDA, which resulted in an immediate 3.8% drop in stock value. Further destabilization occurred after the termination of Allarity's CEO on December 11, 2023, causing a significant decline of 13.4%. Most recently, on July 22, 2024, Allarity disclosed it received a Wells Notice from the SEC concerning the same investigation, leading to another decrease in stock price of 2.4%. This series of events has raised concerns among investors, prompting legal action to address the alleged misconduct and its effects on shareholder value.

As the class action lawsuit progresses, law firms like the Law Offices of Howard G. Smith and the Rosen Law Firm are actively encouraging affected investors to consider their options. With the lead plaintiff deadline set for November 12, 2024, investors who purchased Allarity securities during the specified period may be entitled to compensation through a contingency fee arrangement. This legal framework ensures that investors do not incur out-of-pocket costs while pursuing claims against the company, highlighting the importance of timely action to protect their rights and interests.

In addition to the ongoing legal proceedings, the situation underscores the broader challenges facing Allarity Therapeutics within the competitive landscape of biopharmaceuticals. The company is under increased scrutiny as it navigates regulatory hurdles related to Dovitinib, which could have lasting implications for its future research and development efforts. Stakeholders are closely monitoring how these legal challenges may impact Allarity's operations and its standing in the biopharmaceutical sector.

As Allarity Therapeutics confronts these serious allegations, the company’s path forward remains uncertain. Investors are urged to stay informed and consider their legal options as the situation evolves, particularly in light of the potential ramifications of the ongoing SEC investigation and its impact on the company’s reputation and market performance.